These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 29759926)

  • 1. Drug Repurposing for Viral Infectious Diseases: How Far Are We?
    Mercorelli B; Palù G; Loregian A
    Trends Microbiol; 2018 Oct; 26(10):865-876. PubMed ID: 29759926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug repurposing for new, efficient, broad spectrum antivirals.
    García-Serradilla M; Risco C; Pacheco B
    Virus Res; 2019 Apr; 264():22-31. PubMed ID: 30794895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics.
    Gutierrez-Chamorro L; Felip E; Ezeonwumelu IJ; Margelí M; Ballana E
    Trends Microbiol; 2021 Sep; 29(9):836-848. PubMed ID: 33618979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safe-in-Man Broad Spectrum Antiviral Agents.
    Yao R; Ianevski A; Kainov D
    Adv Exp Med Biol; 2021; 1322():313-337. PubMed ID: 34258746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral activity of cationic amphiphilic drugs.
    Salata C; Calistri A; Parolin C; Baritussio A; Palù G
    Expert Rev Anti Infect Ther; 2017 May; 15(5):483-492. PubMed ID: 28286997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinase Inhibitors as Underexplored Antiviral Agents.
    García-Cárceles J; Caballero E; Gil C; Martínez A
    J Med Chem; 2022 Jan; 65(2):935-954. PubMed ID: 33970631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing drugs targeting epidemic viruses.
    Namasivayam V; Palaniappan S; Vanangamudi M
    Drug Discov Today; 2022 Jul; 27(7):1874-1894. PubMed ID: 35427764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
    Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M
    Front Immunol; 2019; 10():60. PubMed ID: 30761132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug combination therapy for emerging viral diseases.
    Shyr ZA; Cheng YS; Lo DC; Zheng W
    Drug Discov Today; 2021 Oct; 26(10):2367-2376. PubMed ID: 34023496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy.
    Pizzorno A; Padey B; Terrier O; Rosa-Calatrava M
    Front Immunol; 2019; 10():531. PubMed ID: 30941148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections.
    Dos Santos Nascimento IJ; de Aquino TM; da Silva-Júnior EF
    Curr Med Chem; 2021; 28(15):2887-2942. PubMed ID: 32787752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine learning techniques applied to the drug design and discovery of new antivirals: a brief look over the past decade.
    Serafim MSM; Dos Santos Júnior VS; Gertrudes JC; Maltarollo VG; Honorio KM
    Expert Opin Drug Discov; 2021 Sep; 16(9):961-975. PubMed ID: 33957833
    [No Abstract]   [Full Text] [Related]  

  • 13. Human viral diseases: what is next for antiviral drug discovery?
    De Clercq E
    Curr Opin Virol; 2012 Oct; 2(5):572-9. PubMed ID: 22846888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facilitating Antiviral Drug Discovery Using Genetic and Evolutionary Knowledge.
    Xu X; Zhang QY; Chu XY; Quan Y; Lv BM; Zhang HY
    Viruses; 2021 Oct; 13(11):. PubMed ID: 34834924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens.
    Prasad M; Ranjan K; Brar B; Shah I; Lalmbe U; Manimegalai J; Vashisht B; Gaury M; Kumar P; Khurana SK; Prasad G; Rawat J; Yadav V; Kumar S; Rao R
    Curr Drug Metab; 2017; 18(10):942-970. PubMed ID: 28952435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model.
    Everts M; Cihlar T; Bostwick JR; Whitley RJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():155-169. PubMed ID: 27483339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational drug repurposing for viral infectious diseases: a case study on monkeypox.
    Saha S; Chatterjee P; Nasipuri M; Basu S; Chakraborti T
    Brief Funct Genomics; 2024 Sep; 23(5):570-578. PubMed ID: 38183212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial overview: antivirals and resistance: advances and challenges ahead.
    Menéndez-Arias L; Richman DD
    Curr Opin Virol; 2014 Oct; 8():iv-vii. PubMed ID: 25155454
    [No Abstract]   [Full Text] [Related]  

  • 19. Biomolecular Condensates as Novel Antiviral Targets.
    Martin EW; Iserman C; Olety B; Mitrea DM; Klein IA
    J Mol Biol; 2024 Feb; 436(4):168380. PubMed ID: 38061626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases.
    Guo D
    Virol Sin; 2020 Jun; 35(3):253-255. PubMed ID: 32048130
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.